# Pemetrexed

## Alimta inj 100mg

##### 臨採

| TAH Drug Code      | [IALI1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IALI1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | In combination with cisplatin for the treatment of malignant pleural mesothelioma. Monotherapy for the 2nd-line treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer. In combination with cisplatin therapy for the 1st-line treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Dosing             | 500 mg/m2 administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Contraindications  | Severe hypersensitivity to pemetrexed or any component of the formulation. Canadian labeling: Additional contraindications (not in the US labeling): Concomitant yellow fever vaccine.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Adverse Effects    | Common: Itching (1-24%), Rash (16-25%), Constipation (1-51%), Diarrhea (5-37%), Loss of appetite (19-27%), Nausea (12-82%), Pharyngitis, Stomatitis, Vomiting (6-57%), Anemia, All Grades (15-33%), Neutropenia, All Grades (6-56%), Thrombocytopenia, All Grades (1-23%), Cough (21-24%), Dyspnea (21-39%), Fatigue (18-71%), Fever (1-20%) Serious: Peeling of skin, Radiation recall reaction due to cytotoxic therapy, Stevens-Johnson syndrome, Toxic epidermal necrolysis, Gastrointestinal obstruction, Grade 3 and 4 (<1%), Anemia, Grades 3 and 4 (3-6%), Febrile neutropenia (Up to 5% (all Grades); 1-5% (Grade 3 or 4)), Neutropenia, Grades 3 and 4 (3-23%), Thrombocytopenia, Grades 3 and 4 (2-5%), Sensory neuropathy (1%), Renal failure (Up to 5%), Acute lung injury, Interstitial pneumonia, Pulmonary embolism (<1%) |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Lactation          | Hold Breast Feeding                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| More Info          | [UpToDate](https://www.uptodate.com/contents/pemetrexed-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

## ALIMTA inj 500mg

##### 臨採

| TAH Drug Code      | [IALI5](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IALI5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | In combination with cisplatin for the treatment of malignant pleural mesothelioma. Monotherapy for the 2nd-line treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer. In combination with cisplatin therapy for the 1st-line treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Dosing             | 500 mg/m2 administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Contraindications  | Severe hypersensitivity to pemetrexed or any component of the formulation. Canadian labeling: Additional contraindications (not in the US labeling): Concomitant yellow fever vaccine.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Adverse Effects    | Common: Itching (1-24%), Rash (16-25%), Constipation (1-51%), Diarrhea (5-37%), Loss of appetite (19-27%), Nausea (12-82%), Pharyngitis, Stomatitis, Vomiting (6-57%), Anemia, All Grades (15-33%), Neutropenia, All Grades (6-56%), Thrombocytopenia, All Grades (1-23%), Cough (21-24%), Dyspnea (21-39%), Fatigue (18-71%), Fever (1-20%) Serious: Peeling of skin, Radiation recall reaction due to cytotoxic therapy, Stevens-Johnson syndrome, Toxic epidermal necrolysis, Gastrointestinal obstruction, Grade 3 and 4 (<1%), Anemia, Grades 3 and 4 (3-6%), Febrile neutropenia (Up to 5% (all Grades); 1-5% (Grade 3 or 4)), Neutropenia, Grades 3 and 4 (3-23%), Thrombocytopenia, Grades 3 and 4 (2-5%), Sensory neuropathy (1%), Renal failure (Up to 5%), Acute lung injury, Interstitial pneumonia, Pulmonary embolism (<1%) |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Lactation          | Hold Breast Feeding                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| More Info          | [UpToDate](https://www.uptodate.com/contents/pemetrexed-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

